Bleeding during antithrombotic therapy in patients with atrial fibrillation

Archives of Internal Medicine

Volumn 156, Issue 4, 1996, Pages 409-416

  Chesebro, J H ^a   Wiebers, D O ^a   Holland, A E ^a   Bardsley, W T ^a   Litin, S C ^a   Meissner, I ^a   Zerbe, D M ^a   Flaker, G C ^a   Webel, R ^a   Nolte, B ^a   Stevenson, P ^a   Byer, J ^a   Wright, W ^a   Anderson, D C ^a   Asinger, R W ^a   Newburg, S M ^a   Bundlie, S R ^a   Farmer, C C ^a   McBride, R ^a  

^a Stat and Epidemiol Res Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ADULT; AGED; AGING; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMANGIOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; STROKE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR DISORDERS; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; WARFARIN;

EID: 9044251599     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.4.409     Document Type: Article

References (67)

1. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results Circulation. 1991,84 527-539
2. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994,154:1449-1457.
3. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994,343 687-691
4. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
5. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin compared to aspirin for prevention of arterial thromboembolism in atrial fibrillation design and patient characteristics of the Stroke Prevention in Atrial Fibrillation II Study. Cerebrovasc Dis. 1992;2:332-341.
6. Bussey HI, Force RW, Bianco TM, Leonard AD. Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy Arch Intern Med 1992;152:278-282.
7. Landefeld CS, Anderson PA, Goodnough LT, et al. The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol. 1989,42.711-718
8. Coon WW, Willis PW III. Hemorrhagic complications of anticoagulant therapy. Arch Intern Med 1974,133:386-392.
9. Husted S, Andreasen F. The influence of age on the response to anticoagulants. Br J Clin Pharmacol. 1977;4:559-565
10. Landefeld CS, Goldman L. Major bleeding in oupatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy Am J Med. 1989;87 144-152.
11. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladsfoged K. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients J Intern Med. 1991;229:351-355.
12. Petitti DB, Strom BL, Melmon KL. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol. 1989;42 759-764
13. Peyman MA. The significance of haemorrhage during the treatment of patients with the coumarin anticoagulants Acta Med Scand. 1958;162(suppl 339):1-62.
14. Pollard JW, Hamilton MJ, Christensen NA, Achor RWP. Problems associated with long-term anticoagulant therapy: observations in 139 cases Circulation. 1962;25.311-317
15. Roos J, van Joost HE. The cause of bleeding during anticoagulant treatment Acta Med Scand. 1965;178:129-131.
16. Schulman S, Lockner D. Relationship between thromboembolic complications and intensity of treatment during long-term prophylaxis with oral anticoagulants following DVT Thromb Haemost. 1985;53:137-140
17. Van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. Arch Intern Med 1993;153 1557-1562.
18. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897-902.
19. Askey JM. Hemorrhage during long-term anticoagulant drug therapy, I: intracranial hemorrhage. Calif Med. 1966;104:6-10.
20. Levine MN, Raskob G, Hirsh J. Risk of haemorrhage associated with long-term anticoagulant therapy. Drugs 1985;30:444-460.
21. Levine MN, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of anticoagulant treatment. Chest. 1992;102(suppl):352s-363s
22. Barron KD, Fergusson G. Intracranial hemorrhage as a complication of anticoagulant therapy. Neurology. 1959,9:447-455.
23. Lieberman A, Hass WK, Pinto R, et al. Intracranial hemorrhage and infarction in anticoagulated patients with prosthetic heart valves. Stroke 1978;9.18-24
24. Dawson I, van Bockel JH, Ferrari MD, van der Meer FJM, Brand R, Terpstra JL. Ischemic and hemorrhagic stroke in patients on oral anticoagulants after reconstruction for chronic lower limb ischemia Stroke. 1993;24:1655-1663
25. Mattle H, Kohler S, Huber P, Rohner M, Steinsiepe KF. Anticoagulation-related intracranial extracerebral haemorrhage J Neurol Neurosurg Psychiatry. 1989; 52 829-837.
26. Hill AB, Marshall J, Shaw DA A controlled clinical trial of long-term anticoagulant therapy in cerebrovascular disease Q J Med 1960;29:597-609.
27. Kase CS, Robinson RK, Stein RW et al Anticoagulant-related intracerebral hemorrhage Neurology. 1985,35:943-948.
28. Levine M, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy for ischemic cerebral vascular disease. Stroke. 1986;17:111-116
29. Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 1989,95(suppl):27s-36s.
30. Strang RR, Tovi D. Subdural haematomas complicating anticoagulant therapy BMJ 1962;1:845-846
31. Wells CE, Urrea D. Cerebrovascular accidents in patients receiving anticoagulant drugs. Arch Neurol. 1960;5:553-558.
32. Wintzen AR, de Jonge H, Loeliger EA, Bots GTAM. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study Ann Neurol. 1984;16.553-558
33. Davis FB, Estruch MT, Samson-Corvera EB, Voigt GC, Tobin JD. Management of anticoagulation in outpatients: experience with an anticoagulation service in a municipal hospital setting. Arch Intern Med. 1977;137:197-202.
34. Kelton JG, Hirsh J Bleeding associated with antithrombotic therapy Semin Hematol. 1980;17:259-291.
35. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation, a multicenter study. Ann Intern Med. 1993;118:511-520.
36. Forfar JC. A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment. Br Heart J 1979;42:128-132.
37. Forfar JC. Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio. Am Heart J. 1982;103:445-446.
38. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307:1676-1681
39. Landefeld CS, Rosenblatt MW, Goldman L Bleeding in outpatients treated with warfarin, relation to the prothrombin time and important remediable lesions. Am J Med. 1989;87:153-159.
40. Moshos CB, Wong PCY, Sise HS Controlled study of the effective level of long-term anticoagulation JAMA. 1964,190:799-805.
41. Petty GW, Lennihan L, Mohr JP, et al. Complications of long-term anticoagulation. Ann Neurol. 1988,23:570-574.
42. Saour JN, Sieck JO, Mamo LAR, Gallus AS Trial of different intensities of anticoagulation in patients with prosthetic heart valves N Engl J Med. 1990,322: 428-432.
43. Turpie AGG, Hirsh J, Gunstensen J, Nelson H, Gent M Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement Lancet. 1988;1:1242-1245.
44. Zweifler AJ Relation of prothrombin concentration to bleeding during oral anticoagulant therapy its importance in detection of latent organic lesions. N Engl J Med. 1962;267:283-285
45. Wilcox CM, Truss CD. Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy. Am J Med. 1988;84:683-690.
46. Blom G. Statistical Estimates and Transformed Beta Variables New York, NY John Wiley & Sons Inc; 1958.
47. Gurwitz JH, Goldberg RJ, Holden A, Knapie N, Ansell J Age-related risks of long-term oral anticoagulant therapy Arch Intern Med. 1988,148:1733-1736.
48. Second Report of the Sixty Plus Reinfarction Study Research Group Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction Lancet. 1982;1.64-68
49. Eckman MH, Levine HJ, Pauker SG. Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med. 1993,329 696-702
50. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation, does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 1994, 154:1945-1953.
51. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota Mayo Clin Proc. 1995;70.725-733.
52. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food Ann Intern Med. 1994;121.676-683.
53. Landefeld CS, Anderson PA. Guideline-based consultation to prevent anticoagulant-related bleeding: a randomized, controlled trial in a teaching hospital. Ann Intern Med. 1992;116 829-837.
54. McInnes GT, Helenglass G The performance of clinics for outpatient control of anticoagulation. J R Coll Physicians Lond 1987;21 42-45.
55. White RH, McCurdy SA, von Marensdorff H, Woodruff DE Jr, Leftgoff L Home prothrombin time monitoring after the initiation of warfarin therapy a randomized, prospective study. Ann Intern Med. 1989;111:730-737.
56. Kent DL, Vermes D, McDonell M, Henikoff J, Fihn SD. A model for planning optimal follow-up for outpatients on warfarin anticoagulation. Med Decis Making 1992;12.132-141
57. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990,323.1505-1511.
58. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992, 327:1406-1412.
59. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet. 1989;1 175-179.
60. Connolly SJ, Laupacis A, Gent M, et al Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349-355
61. Connolly S for the Atrial Fibrillation Investigators Stroke Prevention in Atrial Fibrillation II Study Lancet. 1994;343.1509
62. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation Chest 1992;102(suppl):426s-433s
63. Staaf G, Norrving B, Nilsson B. Intracerebral hematomas during anticoagulant treatment. Acta Neurol Scand 1987;76:391, Abstract
64. Franke CL, De Jonge J, van Swieten JC, Op de Coul AAW, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke. 1990,21.726-730.
65. Fredriksson K, Norrving B, Stromblad LG Emergency reversal of anticoagulation after intracerebral hemorrhage Stroke 1992;23 972-977
66. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features of patients at risk. Ann Intern Med 1992;116.1-5.
67. Stroke Editorial Office. Major ongoing stroke trials Stroke. 1994;25:541-545.